About
LumiThera, Inc. is a U.S.-based medical device company founded in 2013, led by President & CEO Clark E. Tedford, Ph.D. The company specializes in non-invasive treatments for degenerative eye diseases, particularly dry age-related macular degeneration (AMD), a major cause of blindness globally. LumiThera utilizes photobiomodulation (PBM) technology, which employs specific wavelengths of light to stimulate retinal cells, enhancing energy production and blood flow to improve visual function. Their flagship product, the Valeda Light Delivery System (LT-300), is designed to slow the progression of dry AMD and has received FDA authorization for marketing. This device has shown clinical evidence of improving visual acuity in patients after treatment. The company is committed to research and development, aiming to expand the applications of PBM technology for other retinal diseases. LumiThera has established a strong regulatory framework, including FDA clearance and CE marking, and has secured over $36 million in funding to support its innovative product development and commercialization efforts.
Technologies
Keywords
Company Information
-
Employees 34
-
Founded 2013
-
Annual Revenue $12500000
-
Total Funding $50344475
Location
19578 10th Ave NE, Poulsbo, Washington, United States, 98370-7332
